The development of new cancer drugs is challenging, costly, and time-consuming. As translational research on cancer diagnostics and genomic profiling rapidly evolves, the ability to confidently and efficiently identify specific oncogenes and tumor suppressors involved in oncogenesis is becoming increasingly difficult. 

This brief half-hour webinar is intended for biopharmaceutical and biotechnology professionals who need more efficient ways of discovering, developing, and repurposing drugs for oncology applications. During the session, attendees will explore a demonstration and a use-case presented by Dr. Kyle Nilson, providing insights into the Human Somatic Mutation Database (HSMD)—a new somatic database developed by QIAGEN that contains extensive genomic content relevant to solid tumors and hematological malignancies. 

HSMD is an exceptional resource for biopharmaceutical and biotechnology companies, facilitating the confident evaluation of cancer-related genetic variations by granting access to real-world data. Powered by QIAGEN’s extensive artificial intelligence (AI)-enabled Knowledge Base, robust curation team composed of over 100 expert curators (MD and PhD level), and data from QIAGEN’s professional variant interpretation service (previously N-of-One), HSMD encompasses a vast repository of over 4.7 million meticulously curated genetic alteration findings and variant data over 500,000 somatic patient cases. Attendees will explore how HSMD enables biopharmaceutical and biotechnology companies to gain deeper insights into the molecular cancer profiles, identify therapeutic options, and develop strategies for finding new therapies for a particular cancer type or even for a particular patient.